ArticleBlood advances2025

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Febe Smits et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.